Original ArticleA phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
Under a Creative Commons license
open access
Key words
cobimetinib
triple-negative breast cancer
MEK inhibitor
atezolizumab
programmed death-ligand 1 inhibitor
Cited by (0)
- †
Current affiliation: Department of Medical Oncology, Riviera-Chablais Hospital, Vaud-Valais, Rennaz, Switzerland.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.